Christel Iffland is Senior Vice President of Antibody Technologies at OmniAb. Dr. Iffland joined the OmniAb team and Ligand Pharmaceuticals in 2017 from Merck KGaA/EMD Serono where she previously served as Associate Director of Antibody Technologies, a Senior Scientist of Phage Technologies and Structural Biology and Group Leader of Antibody Display Technologies and was one of the first industry users of the OmniRat® technology. Dr. Iffland supports current and new partnerships and collaborations for OmniAb, providing scientific guidance and input. Additionally, she contributes to the continued growth and next-generation innovation of the technology, and to the technical assessment of new opportunities. Dr. Iffland received her PhD. in molecular and cell biology from the Université de Nice Sophia-Antipolis in Nice, France and completed post-doctoral research training at both the Dana-Farber Cancer Institute at Harvard Medical School and the Albert Einstein College of Medicine. Dr. Iffland is an author of numerous scientific publications and patents.
